Neurocrine Biosciences, Inc.

Hi, everyone, and welcome to today's Neurocrine Biosciences reports, fourth quarter and year-end 2020 results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. You may register to ask a question at any time by pressing the star and 1 on your touchtone phone. Please note this call may be recorded. and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.

Thank you, Chloe. Good afternoon, everyone, and thank you for joining us on our fourth quarter and full year 2020 earnings call. On the call today is Kevin Gorman, our Chief Executive Officer, Matt Abernethy, our Chief Financial Officer, Irie Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. Following our prepared remarks, we will then head into Q&A. So with that, I'll turn it over to Kevin Korman.

Thanks, Todd. Good afternoon. It's good to talk to everyone again. It's only been about three and a half weeks, I think. That's a short period of time. We were able to touch base with many of you, and at that time, we announced our top-line earnings. And also, as we announced those top-line earnings, we told you how encouraged we were that the brand grew during a much worsening pandemic. We also talked about how we view Q1 of 2021, which now we're about a month into. Our message and our view hasn't changed from them. This Q1 is rolling out like all the other first quarters. The first half of Q1 is being dominated by reauthorizations of our existing patients and then prior authorizations of both new patients and those who have changed insurance plans. And again, as always, this is a tale of two quarters. The second half of the quarter is where we expect the normal pace of business to return, but obviously, as stated before, with the impact of COVID still weighing in. Now, Matt and Eric will go into more detail on the 2020 performance and our plans for 2021. But as I look back on 2020, we performed well in all facets of the business, attaining just shy of $1 billion in sales with Ingresa, launching a new brand on Gentis. effectively managing the stop and start of several of our clinical programs and then significantly expanding our pipeline. Now, with regard to that last point, with such a robust pipeline and our continuing commitment to manage responsibly our financial and human resources, we recently made the decision to terminate the Parkinson's program with Voyager. Those resources are being redeployed to fully exploit the near and medium-term opportunities our pipeline holds. and the details of our pipeline will be addressed by Eiry. Looking ahead, we are continuing to focus on our mission of becoming the leading neuroscience company in all three disciplines and that means neurology, neuroendocrinology and neuropsychiatry. Our current commercial medicines along with our pipeline gives us a great foundation to achieve this goal. So with that, I'd like to turn the call over to the rest of the team starting with Matt.